摘要
Abstract
Objective To compare the clinical effect and safety of different doses of mifepristone in treating perimenopausal women with hysteromyoma. Methods Totally 90 perimenopausal women with hysteromyoma were selected and randomly divided into the low-dose group and the high-dose group, 45 cases in each group. The low-dose group was given mifepristone 12. 5 mg/d, while the high-dose group was given mifepristone 25 mg/d. The two groups were treated continuously for 3 months. Results After treatment, the volume of uterine and hysteromyoma in the two groups were significantly decreased ( P < 0. 05 ) , the levels of LH, FSH, PRL, P and E2 in serum were significantly improved ( P < 0. 05 ) , there was no significant difference in the clinical effective rate in two groups ( 91. 11％ vs 86. 67％, P > 0. 05 ) , the incidence rate of adverse reactions in the high-dose group was significantly higher than that in the low-dose group ( 22. 22％ vs 6. 67％, P < 0. 05 ) . Conclusion The clinical effect of mifepristone in the treatment of perimenopausal women with hysteromyoma is good, the small dose ( 12. 5 mg/d ) program should be selected to significantly reduce the incidence of adverse reactions.关键词
剂量/米非司酮/围绝经期/子宫肌瘤/临床疗效/安全性Key words
dose/mifepristone/perimenopause/hysteromyoma/clinical effect/safety分类
医药卫生
